Title :

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the French-Ric Network

Author(s) :

Salmon, Jean-Hugues [Auteur]
Hôpital Maison Blanche
Letarouilly, Jean-Guillaume [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Service de rhumatologie[Lille]
Goëb, Vincent [Auteur]
CHU Amiens-Picardie
Kanagaratnam, Lukshe [Auteur]
Hôpital universitaire Robert Debré [Reims] [CHU Reims]
Coquerelle, Pascal [Auteur]
Centre Hospitalier de Béthune [CH Béthune]
Guyot, Marie-Hélène [Auteur]
Hôpital Victor Provo [Roubaix]
Houvenagel, Eric [Auteur]
Hôpital Saint Philibert [Lomme]
Lecuyer, Nicolas [Auteur]
Marguerie, Laurent [Auteur]
Institut Calot [Fondation Hopale]
Morel, Gauthier [Auteur]
Centre hospitalier [Valenciennes, Nord]
Baudens, Guy [Auteur]
Gervais, Elisabeth [Auteur]
Service de rhumatologie [Poitiers]
Flipo, René-Marc [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Roger Salengro [Lille]

Journal title :

Journal of clinical medicine

Pages :

1528

Publisher :

MDPI

Publication date :

2020-05-19

ISSN :

2077-0383

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence ...
Show more >Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Marrow Adiposity & Bone Lab (MABLab) - ULR 4490

Source :

Harvested from HAL